TrialThe Lancet. Oncology2016

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.

Joel W Neal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.